EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

MLA

Paez, J.Guillermo, et al. “EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy.” Science (New York, N.Y.), vol. 304, no. 5676, June 2004, pp. 1497–500. EBSCOhost, https://doi.org/10.1126/science.1099314.

APA

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E., & Meyerson, M. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (New York, N.Y.), 304(5676), 1497–1500. https://doi.org/10.1126/science.1099314

Chicago

Paez, J Guillermo, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, et al. 2004. “EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy.” Science (New York, N.Y.) 304 (5676): 1497–1500. doi:10.1126/science.1099314.